This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldberg, L. Articles by Kloog, Y. Search for Related Content PubMed PubMed Citation Articles by Goldberg, L. Articles by Kloog, Y.

A Ras Inhibitor Tilts the Balance between Rac and Rho and Blocks Phosphatidylinositol 3-Kinase–Dependent Glioblastoma Cell Migration

Department of Neurobiochemistry, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel

Requests for reprints: Yoel Kloog, Department of Neurobiochemistry, The George S. Wise Faculty of Life Sciences, Tel Aviv University, 69978 Tel-Aviv, Israel. Phone: 972-3-640-9699; Fax: 972-3-640-7643; E-mail: kloog{at}post.tau.ac.il.

Glioblastoma multiforme are highly aggressive tumors for which no adequate treatment has yet been developed. Glioblastoma multiforme show large amounts of active Ras, considered an appropriate target for directed therapy. Here, we show that the Ras inhibitor S-trans, trans-farnesyl thiosalicylic acid (FTS) can avert the transformation of human glioblastoma multiforme cells by inhibiting both their migration and their anchorage-independent proliferation. FTS, by down-regulating Ras activity in glioblastoma multiforme cells, inhibited phosphatidylinositol 3-kinase signaling, resulting in decreased activity of Rac-1. At the same time, activation of RhoA was increased. These two small GTPases are known to control the arrangement of the actin cytoskeleton. By tilting the balance between Rac-1 and RhoA activities, FTS caused the glioblastoma multiforme cells to undergo profound changes in morphology, including rearrangement of actin into stress fibers and assembly of focal adhesions, both of which are governed by RhoA signaling. These morphologic changes allowed strong attachment of the cells to the matrix, rendering them immobile. The results show that FTS should be considered as a candidate drug for glioblastoma multiforme therapy because it targets not only cell proliferation but also cell migration and invasion, which together constitute the most problematic aspect of these malignancies. (Cancer Res 2006; 66(24): 11709-17)

This article has been cited by other articles:

				T. A. Ulrich, E. M. de Juan Pardo, and S. Kumar The Mechanical Rigidity of the Extracellular Matrix Regulates the Structure, Motility, and Proliferation of Glioma Cells Cancer Res., May 15, 2009; 69(10): 4167 - 4174. [Abstract] [Full Text] [PDF]

				H. Li, C. Y. Ung, X. H. Ma, B. W. Li, B. C. Low, Z. W. Cao, and Y. Z. Chen Simulation of crosstalk between small GTPase RhoA and EGFR-ERK signaling pathway via MEKK1 Bioinformatics, February 1, 2009; 25(3): 358 - 364. [Abstract] [Full Text] [PDF]

				L. Goldberg, A. Ocherashvilli, D. Daniels, D. Last, Z. R. Cohen, G. Tamar, Y. Kloog, and Y. Mardor Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats Mol. Cancer Ther., November 1, 2008; 7(11): 3609 - 3616. [Abstract] [Full Text] [PDF]

				C.-L. Lin, J.-Y. Wang, J.-Y. Ko, K. Surendran, Y.-T. Huang, Y.-H. Kuo, and F.-S. Wang Superoxide Destabilization of {beta}-Catenin Augments Apoptosis of High-Glucose-Stressed Mesangial Cells Endocrinology, June 1, 2008; 149(6): 2934 - 2942. [Abstract] [Full Text] [PDF]

				B. Ding and P. Lengyel p204 Protein Is a Novel Modulator of Ras Activity J. Biol. Chem., February 29, 2008; 283(9): 5831 - 5848. [Abstract] [Full Text] [PDF]

				Y. Hashimoto, M. Parsons, and J. C. Adams Dual Actin-bundling and Protein Kinase C-binding Activities of Fascin Regulate Carcinoma Cell Migration Downstream of Rac and Contribute to Metastasis Mol. Biol. Cell, November 1, 2007; 18(11): 4591 - 4602. [Abstract] [Full Text] [PDF]